Autosomal dominant retinitis pigmentosa (ADRP) has been linked to mutations in the gene encoding rhodopsin. Most RP-linked rhodopsin mutants are unable to fold correctly in the endoplasmic reticulum, are degraded by the ubiquitin proteasome system, and are highly prone to forming detergent-insoluble high molecular weight aggregates. Here we have reported that coexpression of folding-deficient, but not folding-proficient, ADRP-linked rhodopsin mutants impairs delivery of the wild-type protein to the plasma membrane. Fluorescence resonance energy transfer and co-precipitation studies revealed that mutant and wild-type rhodopsins form a high molecular weight, detergentinsoluble complex in which the two proteins are in close (<70 Å) proximity. Co-expression of ARDP-linked rhodopsin folding-deficient mutants resulted in enhanced proteasome-mediated degradation and steady-state ubiquitination of the wild-type protein. These data suggested a dominant negative effect on conformational maturation that may underlie the dominant inheritance of ARDP.
Autosomal dominant retinitis pigmentosa (ADRP) has been linked to mutations in the gene encoding rhodopsin. Most RP-linked rhodopsin mutants are unable to fold correctly in the endoplasmic reticulum, are degraded by the ubiquitin proteasome system, and are highly prone to forming detergent-insoluble high molecular weight aggregates. Here we have reported that coexpression of folding-deficient, but not folding-proficient, ADRP-linked rhodopsin mutants impairs delivery of the wild-type protein to the plasma membrane. Fluorescence resonance energy transfer and co-precipitation studies revealed that mutant and wild-type rhodopsins form a high molecular weight, detergentinsoluble complex in which the two proteins are in close (<70 Å) proximity. Co-expression of ARDP-linked rhodopsin folding-deficient mutants resulted in enhanced proteasome-mediated degradation and steady-state ubiquitination of the wild-type protein. These data suggested a dominant negative effect on conformational maturation that may underlie the dominant inheritance of ARDP.
Rhodopsin is a G-protein-coupled receptor that mediates light-driven signal transduction in rod photoreceptors (1) . Heterologous expression of rhodopsin in mammalian cell culture appears to faithfully recapitulate its synthesis, folding, and assembly with its native chromophore, 11-cis retinal (2) , and thus is a tractable model system to understand the early events in rhodopsin biogenesis. Like other integral membrane proteins, nascent rhodopsin molecules are co-translationally inserted into the endoplasmic reticulum membrane where they undergo N-linked glycosylation and conformational maturation prior to export to the Golgi apparatus and delivery to the plasma membrane (3) . In rod photoreceptor cells, rhodopsin is delivered to the outer segments via vesicular transport on axonemal microtubules (reviewed in Ref. 3) .
Retinitis pigmentosa (RP) 1 is a group of progressive diseases of the retina (4). With a combined incidence of ϳ1 in 3500, RP is the most prevalent Mendelian degenerative retinopathy in humans. The majority of RP is inherited as an autosomal dominant (AD) trait linked to over 100 missense mutations in the rhodopsin gene (5) , although ADRP has also been linked to genes encoding other structural components of the rod outer segment and the phototransduction cascade (6) . ADRP-linked rhodopsin mutations have been assigned to two classes based on their intracellular behavior when expressed in cell culture (7, 8) . Class I mutants resemble wild-type in steady-state level, plasma membrane localization, and the ability to form functional chromophore when assembled with 11-cis retinal (9) . Class I mutants cluster near the C-terminal domain of rhodopsin and appear to be defective in trafficking to outer segments, possibly by virtue of their inability to bind to the Tctex-1 subunit of dynein/dynactin (10) . The most prevalent rhodopsinlinked ADRP mutations are class II mutants. When expressed in human embryonic kidney (HEK) cells, class II mutant rhodopsins accumulate to lower steady-state levels compared with class I mutants or to wild-type (WT) rhodopsin protein. Class II mutants are unable to assemble with 11-cis retinal and are partially or completely retained in the ER, suggesting a defect in an early step in the folding or assembly pathway (7, 9) . Indeed, class II mutants such as P23H-rhodopsin and G188R-rhodopsin exhibit prolonged association with molecular chaperones compared with WT rhodopsin (11, 12) and are substrates for degradation by the ubiquitin-proteasome system (13) . Consistent with a severe defect in folding, P23H is highly prone to form SDS-resistant high molecular weight multimers and non-ionic detergent-insoluble aggregates (13) . In these respects, class II rhodopsin mutations resemble mutations that underlie the pathogenesis of other dominantly inherited neurodegenerative diseases, including familial Parkinson and familial amyotrophic lateral sclerosis (14) . Indeed, like the mutations in SOD1 linked to familial amyotrophic lateral sclerosis, the Ͼ100 missense mutations responsible for ADRP are essentially randomly distributed throughout the sequence of rhodopsin, suggesting that class II rhodopsin-linked ADRP is a "conformational disease" (15) .
Despite a wealth of studies investigating the genetic, biochemical, and biophysical properties of ADRP-linked rhodopsin mutants, the molecular mechanisms by which these mutations cause retinal degeneration remain poorly understood. A key to elucidating the pathogenic mechanism lies in unraveling the molecular basis of dominant inheritance, which could result from either a loss-of-function (i.e. dominant interference) or a gain-of-function mechanism.
Here we have reported that class II mutants interfere with the biosynthetic maturation of WT rhodopsin, leading to retention of the latter in the endoplasmic reticulum and recruitment into oligomeric detergent-insoluble complexes. Our data indicated that this dominant interference results from a direct physical interaction between mutant and wild-type proteins and has important implications for the development of rational pharmacological and genetic interventions for the treatment of ADRP.
MATERIALS AND METHODS
Antibodies, Plasmids, and Other Reagents-The following antibodies were used in this study: Rho1D4 (16) (monoclonal; gift from R. Molday, University of British Columbia), B6-30 (17, 18) (monoclonal; gift from P. Hargrave, University of Florida), and anti-ubiquitin (polyclonal; Chemicon). S-protein HRP and S-protein-agarose were purchased from Novagen. Wild-type and P23H rhodopsin in pRK were obtained from J. Nathans (Johns Hopkins University). The ⌬F508-CFTR-FLAG construct has been described earlier (19) . V345M (13, 20) and G188R were made by site-directed mutagenesis using QuikChange® (Stratagene, La Jolla, CA). YFP and CFP rhodopsin and P23H plasmids have been described previously (20) . Rho-Myc and Rho-S were made by annealing oligonucleotides corresponding to the c-Myc decapeptide (EQKLI-SEEDL) or the 15-amino acid S-peptide (KETAAAKFERQHMDS) between the HindIII and BamHI sites at the C terminus of human rhodopsin in the Rho-YFP plasmid. A stop codon was inserted at the end of the S-peptide coding sequence to prevent YFP from being translated.
Cell Culture-HEK-293 cells were maintained in Dulbeco's modified Eagle's medium and transfected as described previously (21) . Transient transfections were carried out by adding plasmid DNA as a calcium phosphate precipitate (22) . Each plasmid was introduced at 3 g for an ϳ40% confluent 10-cm dish of cells, and the total was made to 8 g with empty vector.
Western Blots, S-Protein Pulldowns, and Deglycosylation AssaysCell pellets from transfected and washed HEK cells were lysed in 150 l of ice-cold buffer A (PBS, pH 7.5, 1% Triton X-100) plus protease inhibitor mixture (Roche Applied Science) for 5 min on ice. They were centrifuged at 15,000 ϫ g for 15 min, and supernatants were recovered. For Western blotting, lysates were separated on Ready Gel precast 4 -15% gradient SDS-PAGE (Bio-Rad, Hercules, CA) and electroblotted to nitrocellulose membranes. Chemiluminescence detection was carried out with the ECL detection kit (Amersham Biosciences). For S-protein pulldowns, lysates were diluted 1:10 with PBS containing protease inhibitors to achieve a final detergent concentration of 0.1%. Lysates were precleared with glutathione-agarose for 2 h at 4°C, followed by overnight incubation with S-protein-agarose (Novagen). Beads were washed, in order, with PBS ϩ 0.1% Triton X-100, PBS ϩ 0.02% SDS, PBS. Elution was performed with 1ϫ sample buffer (ϩ␤-mercaptoethanol). For endoglycosidase H and PNGase (Roche Applied Science) digestions, elution from S-protein-agarose pulldowns was performed with 0.8% SDS (ϩ␤-mercaptoethanol). Endo H or PNGase digestions were then carried out for 1 h at 24°C in a 10:1 dilution with the buffer supplied by the manufacturer. S-protein HRP was used at a ratio of 1:2000 in PBS containing 0.1% Triton X-100 and 5% milk powder (PBSTM).
Pulse-Chase Analysis-Cells were starved for cysteine/methionine for 30 min and then labeled with [ 35 S]cysteine/methionine for 10 min. They were scraped off the plate and collected by centrifugation at 6,000 rpm in a microfuge. Cells were lysed in 100 l of buffer A ϩ 2 mg/ml bovine serum albumin and spun at 15,000 ϫ g for 15 min to remove detergent-insoluble material. Supernatants were diluted 1:10 with PBS to achieve a final detergent concentration of 0.1%. Pulldown with Sprotein-agarose, followed by Western blotting, was performed as described in the previous paragraph. Input lysates were normalized for total 35 S counts as described earlier (23) . For Mg132 treatments, cells were incubated with 10 M of Mg132 throughout the starvation, labeling, and chase period.
Fluorescence Microscopy-Cells were harvested for microscopy as described in (13) . Epifluorescence micrographs were obtained on a Zeiss Axiovert microscope with a ϫ63 objective (NA 1.4). Digital (12-bit) images were acquired with a cooled charge-coupled device (CCD) (Princeton Instruments, Trenton, NJ) and processed by using METAMORPH software (Universal Imaging, Media, PA). The excitation filters, dichroics, and emission filters have been described before (13) .
Fluorescence Resonance Energy Transfer (FRET) Measurements-FRET was determined as described previously (20) . Fluorescence spectra were recorded on suspended cells (ϳ10 6 cells/ml) in a Spex fluorolog fluorometer with a Spex 1620 dual grating emission monochromator (Spex Industries, Metuchen, NJ). FRET measurements were made by exciting the donor (CFP) at 425 nm and monitoring the emission spectrum between 450 and 600 nm. All FRET spectra were corrected for background YFP fluorescence using a non-FRET pair consisting of identical amounts of YFP fusion construct and unlabeled rhodopsin (wild-type or mutant). Intrinsic YFP fluorescence was recorded for the background subtraction procedure (20) by excitation at 490 nm and emission between 505-600 nm. Slit widths were 2 mm for all experiments.
RESULTS

Class II Mutants Impair Localization and Processing of WT
Rhodopsin-To test whether expression of mutant rhodopsin can influence the biosynthesis and trafficking of WT rhodopsin, HEK-293 cells co-transfected with a class II mutant (P23H-CFP) and wild-type (Rho-YFP) rhodopsin were imaged simultaneously to assess the steady-state distributions of the two proteins (Fig. 1A) . In this experiment, as in all of the experiments reported here, the two rhodopsin plasmids were introduced at equal concentration, matching the ratio of the two alleles present in the genome of ADRP heterozygotes. We have previously established that the presence of the fluorescent protein (green fluorescent protein, CFP, YFP) appended to the C terminus of rhodopsin has no discernable effect on its folding or intracellular distribution (13, 20) . As expected from previous studies on class II mutants (2, 7-9, 13, 24), P23H-CFP exhibited an exclusively intracellular distribution, consistent with its inability to mature from the ER to distal compartments of the secretory pathway (Fig. 1A) . Strikingly, in cells co-expressing the two proteins, the distribution of Rho-YFP overlapped considerably with that of P23H-CFP, displaying extensive colocalization within intracellular compartments. Unlike the mutant protein, Rho-YFP was also evident at the cell periphery, suggesting that the impairment of delivery of WT rhodopsin to the plasma membrane in the presence of P23H was not complete. In the occasional cell that expressed wild-type rhodopsin in the absence of detectable mutant protein, Rho-YFP was present in its normal, predominantly plasma membrane distribution (Fig. 1A, arrowhead) . These observations suggest that P23H may alter the folding and/or trafficking of WT rhodopsin.
To clarify the biochemical effect of P23H on WT rhodopsin, a WT rhodopsin construct with a 15-amino acid C-terminal S tag was created (Rho-S), so that the synthesis and maturation of tagged WT rhodopsin could be selectively monitored in the presence of mutant rhodopsin. Attachment of small C-terminal epitope tags, such as c-Myc, does not alter either the processing of rhodopsin, its ability to bind retinal, or its ability to activate transducin (25) . Fig. 1B shows that Rho-S can be selectively detected with S-protein HRP (left panel). The 1D4 anti-rhodopsin monoclonal antibody recognizes the last 8 C-terminal residues of rhodopsin (16, 26) only in the context of an unmodified C terminus (26) . Thus, incorporation of the C-terminal S tag (or YFP) completely abrogates recognition by 1D4 (right panel).
Comparison of WT rhodopsin and Rho-S banding patterns, reflecting the relative levels of different WT rhodopsin glycoforms, suggests that introduction of the S tag does not alter the trafficking properties of rhodopsin.
To test whether P23H influences the intracellular trafficking of WT rhodopsin, cells were co-transfected with Rho-S together with untagged P23H (or WT rhodopsin as a control) and analyzed for Rho-S expression by S-protein blot overlay (Fig. 1C) .
In the presence of untagged WT rhodopsin (lane 2), Rho-S migrated as a set of bands between ϳ35-55 kDa, with the predominant species at ϳ40 kDa (block arrow) corresponding to the mature, complex glycosylated form. In the presence of P23H (lane 3), there was a marked decrease in the intensity of this 40-kDa band and a concomitant increase in the intensity of a 35-kDa band (solid arrow) corresponding to core-glycosylated Rho-S. The identities of these species were confirmed by treatment of S-protein pulldowns with endoglycosidases F (or PNGase, which cleaves all N-linked oligosaccharides) and H (which cleaves only high mannose oligosaccharides character-istic of glycoproteins in a pre-Golgi compartment) (Fig. 1D) . These data indicated that P23H, which is not able to fold into a transport-competent state, has a dominant effect in preventing the maturation of WT rhodopsin. To test whether this effect is specific for P23H, we co-expressed Rho-S together with a class I mutant (V345M) or a different class II mutant, G188R, and probed immunoblots of the lysates with S-protein HRP (Fig. 1E) . Expression of the class I mutant had no detectable effect on Rho-S processing, as indicated by the predominance of the complex glycosylated form in immunoblots probed with S-protein HRP. By contrast, expression of G188R resulted in a severe reduction in the fraction of mature Rho-S, suggesting that dominant suppression of WT rhodopsin maturation may be a property shared among class II mutants.
Direct Interaction between Mutant and WT Rhodopsin-One possible mechanism by which P23H might influence the mat- uration of WT rhodopsin is by depleting chaperones or other ER quality control factors required for correct folding of the wildtype protein. To test this possibility, cells were co-transfected with Rho-Myc and an unrelated integral membrane protein, the ⌬F508 mutant of the cystic fibrosis transmembrane conductance regulator (CFTR). This protein is quantitatively unable to fold (23, 27) and is subject to ER-associated degradation via a ubiquitin-and proteasome-dependent process (21), similar to that described for class II mutants of rhodopsin (13) (Fig.  2A) . Like P23H, ⌬F508 was localized exclusively to intracellular compartments; at the levels used in this experiment, it was present mainly in the ER, as revealed by immunofluorescence microscopy (left panel). By contrast, in the same cells WT rhodopsin exhibited a predominantly plasma membrane distribution (right panel). These findings suggested that the effect of P23H co-expression on WT rhodopsin distribution is not simply a consequence of a generalized saturation, or impairment, of the ER quality control machinery.
An alternative mechanism by which P23H expression could influence WT rhodopsin maturation is by direct interaction of the two proteins during, or shortly following, synthesis on ER membranes. To assess whether P23H and WT rhodopsin interact, protein-S-agarose was used to pull down Rho-S from lysates of cells co-transfected with equal plasmid amounts of P23H and Rho-S. The affinity-purified material was then subjected to immunoblotting using 1D4, which selectively recognizes only untagged rhodopsin (Fig. 2B) . Analysis of the input material (left panel) indicated that P23H and WT rhodopsin were expressed at comparable levels and confirmed our previous finding (13) that, whereas WT rhodopsin migrates as a predominant, somewhat broad, species bearing complex oligosaccharides, P23H migrates primarily as multimers and, to a lesser extent, monomers, of a core-glycosylated form. The 1D4 immunoreactive material from cells co-expressing P23H and Rho-S that bound to S-protein-agarose (right panel) was composed exclusively of dimers and higher multimers. By contrast, only background levels of 1D4 immunoreactivity were detected in pulldowns of cells co-expressing Rho-S and WT rhodopsin. No 1D4 immunoreactive material was detectable in eluates from control transfections that express WT rhodopsin lacking an S tag, confirming the specificity of the pulldown. These data demonstrated that P23H can form a complex with WT rhodop- Fig. 1D . C, direct interaction between P23H and WT rhodopsin assessed by FRET. sin. Moreover, the absence of detectable P23H monomer in the bound fraction suggested that such complexes are extremely stable, as they were not disrupted under the denaturing conditions of SDS-PAGE.
The presence of P23H in pulldowns of Rho-S could be due to a direct interaction between P23H and WT rhodopsin or to an indirect interaction, i.e. formation of a complex consisting of other proteins that bind to both the mutant and wild-type proteins. One way to discriminate between these two possibilities is FRET. This technique involves the transfer of energy from a fluorescent donor in its excited state to another excitable moiety, the acceptor, via non-radiative dipole-dipole interactions. This energy transfer process is highly sensitive to the distance and the orientation between the two fluorophores, typically occurring over a donor-acceptor separation of ϳ10 -100 Å, making FRET an ideal technique to study direct proteinprotein interaction (28) . To determine whether the interaction between P23H and WT rhodopsin was direct, we measured FRET between P23H-CFP and Rho-YFP (Fig. 2C) . Fluorescence emission spectra were recorded on suspensions of cells transfected with P23H-CFP together with either Rho-YFP (dotted line) or untagged WT rhodopsin (solid line) as a control. Both spectra revealed prominent emission peaks at 476 and 505 nm, corresponding to CFP emission, whereas the shoulder at 525 nm reflected the sensitized emission from YFP due to energy transfer from CFP. This enhancement of emission at 525 nm, together with a corresponding decrease in emission at 476 nm, indicated that P23H and WT rhodopsin were in close (Ͻ70 Å) proximity and, therefore, strongly supported the conclusion that the two proteins interact directly with one another.
P23H Interferes with Maturation of Nascent WT Rhodopsin-There are two possibilities to account for the accumulation of WT rhodopsin in a core-glycosylated form in the presence of P23H. P23H could impair the folding of WT rhodopsin, causing WT rhodopsin molecules that would be otherwise delivered to the plasma membrane to be retained in the ER. Alternatively, the presence of P23H could accelerate the turnover of WT rhodopsin at the plasma membrane, thereby resulting in a lower steady-state level of the mature form compared with the core-glycosylated form. To discriminate between these two possibilities, we used pulse-chase analysis to assess the effect of P23H co-expression on the fate of newly synthesized WT rhodopsin (Fig. 3) . Pulse-labeled Rho-S expressed alone (data not shown, but see Ref. 7) or together with ⌬F508 (Fig.  3A, left panel) migrated as a ϳ35-kDa species, corresponding to the core-glycosylated protein (solid arrow). This species was chased to a broad band between 40 -55 kDa, corresponding to the post-ER, complex glycosylated protein (block arrow). The core-glycosylated, ϳ35-kDa Rho-S species disappeared with t1 ⁄2 ϳ60 min (Fig. 3C) , similar to the rate previously reported for untagged WT rhodopsin (7) . By contrast, the presence of P23H, expressed at equal gene dosage compared with Rho-S, severely retarded the rate at which core-glycosylated rhodopsin disappeared, exhibiting a t1 ⁄2 Ͼ400 min (Fig. 3A, right panel, and B) . Expression of P23H correspondingly reduced the fractional rate at which Rho-S was converted to the 40 -55-kDa mature form. The pulldown of P23H and Rho-S, but not ⌬F508ϩRho-S, also exhibited a band of ϳ75 kDa, which is similar to that seen in the steady-state pulldown in Fig. 2B and potentially represents dimeric P23H. Thus, P23H co-expression interfered with the maturation of WT rhodopsin, leading to its retention in a compartment proximal to the medial/cis Golgi.
P23H Co-expression Enhances WT Rhodopsin Degradation by the Ubiquitin Proteasome System-Secretory and integral membrane proteins that are unable to fold in the ER, including P23H, are ultimately subject to degradation by the ubiquitin proteasome system following dislocation from or across the ER membrane (29) . To assess the extent to which newly synthesized Rho-S is targeted to this degradation system in the presence of P23H, we used a pulse-chase protocol to assess the stability of core-glycosylated Rho-S (Fig. 4, A and B) . Inclusion of the proteasome inhibitor, MG132, during the chase increased the amount of label in core-glycosylated Rho-S in cells co-expressing Rho-S and P23H. By contrast, MG132 had a minimal effect on core-glycosylated Rho-S when co-expressed with ⌬F508 CFTR or the folding-proficient class I mutant, V345M. To verify that coreglycosylated Rho-S was being targeted to the ubiquitin proteasome system, we assessed incorporation of ubiquitin into Rho-S (Fig. 4C) . When Rho-S was expressed in the absence of P23H (co-transfected with ⌬F508) only low levels of ubiquitin were detected when immunoblots of S-protein pulldowns were probed with antibody to ubiquitin (upper panel). However, pulldowns from cells expressing P23H revealed vastly enhanced reactivity with anti-ubiquitin. The amount of total rhodopsin in the two pulldowns was comparable, as assessed by probing the S-protein pulldowns with the B6 -30 antibody (lower panel), which recognizes all forms of rhodopsin (i.e. it does not discriminate between the tagged and untagged protein). We therefore concluded that a greater fraction of the total rhodopsin is ubiquitinated when expressed in the presence of P23H than in the presence of ⌬F508, an unrelated protein that, like P23H, is incapable of folding in 35 S]Met/Cys and chased in unlabeled medium for the times indicated. Detergent lysates of the labeled cells were pulled down with S-protein-Sepharose followed by SDS-PAGE and phosphorimage analysis. Lane 1, pulse-labeled untransfected cells. The dashed simple arrow points to an ϳ75-kDa band that is found only in the P23H ϩ Rho-S co-expression and potentially represents dimeric P23H. Other arrows as in Fig. 1B . B, quantification of phosphorimage data for the coreglycosylated form of rhodopsin in co-expression of Rho-S with P23H (filled squares) or ⌬F508 (open squares). Data are representative of four independent trials. the ER. Although this experiment did not allow us to determine which species (P23H, Rho-S, or both) gets ubiquitinated, the complex of P23H and Rho-S as a whole represents a polyubiquitinated entity that is targeted for degradation by the proteasomal machinery.
DISCUSSION
In principle, two types of mechanisms could account for the dominance of mutant rhodopsin alleles in ADRP inheritance. One possibility is that mutations could impart a toxic property upon the protein product of the mutant rhodopsin gene; accumulation of such toxic proteins would ultimately result in photoreceptor death. Alternatively, mutant rhodopsin could exert a direct dominant negative influence on the function, stability, assembly, or intracellular trafficking of the wild-type protein.
The data presented in this report support the latter mechanism, although, as will be discussed below, the two mechanisms are not mutually exclusive.
Several lines of evidence support the conclusion that class II mutants dominantly interfere with WT rhodopsin biosynthesis and folding via direct interaction with the wild-type protein.
First, fluorescence microscopy and immunoblot analysis revealed that co-expression of the class II mutants, P23H or Fig. 3 and chased for the times indicated in the absence or presence of MG132. The mobility of core-glycosylated and mature Rho is indicated by simple and block arrows, respectively. B, fraction of core-glycosylated Rho-S remaining after a 5-h chase in the absence (white bars) or presence (hatched bars) of MG132 from cells co-expressing Rho-S with P23H or control plasmid. Control plasmid represents pooled data from co-transfections with V345M and ⌬F508, which were not significantly different from one another. Data are means from four independent experiments. Error bars represent S.E. C, the complex of Rho-S and P23H is ubiquitylated. Lysates from cells co-transfected with Rho-S together with either ⌬F508 (lane 2) or P23H (lane 3) were purified on S-protein-agarose and subjected to immunoblot analysis with antibody to ubiquitin (upper panel) or Rho B6 -30, a rhodopsin-specific antibody that recognizes both tagged and untagged forms of Rho (and P23H). Arrows as in Fig. 1B. G188R, together with the wild-type protein (WT rhodopsin) at equivalent gene dosage led to retention and/or mislocalization of WT rhodopsin in the ER. This effect was specific for class II mutants; co-expression of WT rhodopsin or a class I mutant had no effect on the intracellular distribution or glycosylation state of WT rhodopsin. Second, co-expression of an unrelated folding-defective mutant polytopic membrane protein, ⌬F508 CFTR, did not cause WT rhodopsin mislocalization or impairment of WT rhodopsin maturation, suggesting that the dominant negative effect of class II mutants is not simply a consequence of saturating the ER "quality control" machinery. Third, stable oligomers, but not monomers, of P23H were specifically bound to S-tagged rhodopsin purified by S-protein affinity chromatography, indicating that mutant and wild-type rhodopsins were part of an oligomeric complex. Our ability to detect energy transfer between co-expressed Rho-CFP and P23H-YFP strongly supported the conclusion that this interaction was direct. Fourth, P23H co-expression suppressed the conversion of pulse-labeled core-glycosylated Rho-S to a form bearing mature, complex oligosaccharides, directly demonstrating that the presence of the mutant interfered with the maturation of the wild-type protein through the secretory pathway. Finally, in the presence of class II mutants, the complex of P23H and core-glycosylated Rho-S became ubiquitylated and was degraded by proteasomal machinery.
Previous studies have examined the effect of folding-incompetent rhodopsin mutants on the intracellular distribution and processing of WT rhodopsin (24, 38, 39) . Although the pioneering studies in Drosophila show a defect in processing of WT rhodopsin in the presence of misfolded mutants, they do not demonstrate the mechanism or the consequences of this effect. The experiment by Saliba et al. was the first with mammalian rhodopsin, and they nicely showed that expression of unlabeled P23H can cause an increase in aggresome-like inclusion bodies formed by green fluorescent protein-tagged WT rhodopsin in a co-transfection of the two (24) . However, unlike the present work in which the wild-type and mutant alleles were expressed at equal DNA ratios, matching the conditions found in ADRP heterozygotes, the earlier experiment was performed with a mutant: wild-type ratio of 10:1. Although this is an intriguing observation, the data did not indicate a colocalization or an interaction between P23H and WT rhodopsin or quantify the effect on processing of WT rhodopsin in the presence of P23H. The experiments in the current study followed up on these earlier observations. They have quantified the effect of P23H expression of WT rhodopsin processing at a physiologically relevant mutant:wild-type DNA ratio of 1:1 and elaborated the mechanism of this effect and the consequence of ER retention of WT rhodopsin in the presence of P23H.
The finding of a dominant negative effect of class II mutant rhodopsin on WT rhodopsin folding and/or maturation is consistent with an oligomeric assembly state for rhodopsin, a conclusion that is inconsistent with the widely held view of rhodopsin as a monomer in its native environment (30) . This view, originating in optical measurements of rotational and translational diffusion performed during the early 1970s (31), has recently been challenged by high resolution atomic force microscopy studies of native disk membranes that show rhodopsin arranged in paracrystalline arrays of precisely aligned double rows of membrane protrusions that likely correspond to rows of rhodopsin dimers (32, 33) . This emerging view of rhodopsin organization in retina is consonant with biochemical and biophysical studies demonstrating that other G-proteincoupled receptors, including those in the same subfamily as rhodopsin, are dimers and depend critically upon dimerization for both function and biosynthetic assembly (34, 35) .
A point of interest is the identity of the ϳ35-kDa core-glycosylated band in the pulse-chase experiment when P23H and Rho-S are co-expressed (Fig. 3) . It is reasonable to suppose that both Rho-S and P23H should be present in the pulldown with S-protein-agarose by virtue of their interaction. As shown by Sung et al. (7) , P23H that is synthesized in the ER is rapidly degraded with a half-life that can estimated to be ϳ120 -150 min. Making an extrapolation, this would imply that, at most, 10 -20% of P23H should be present at 270 min of chase time. However, in the co-transfection of Rho-S with P23H, there is ϳ60% of core-glycosylated material still present at the end of the chase. This implies that at least 40 -50% of the material, from these estimates, is Rho-S alone. However, if it is an oligomeric P23H that nascently associates with Rho-S, then virtually all of the monomeric core-glycosylated material should be Rho-S. Supporting this latter idea is the observation that a ϳ75-kDa band, consistent with the migration of dimeric P23H, is present in the co-transfection of Rho-S with P23H, but not with ⌬F508 (Fig. 3A, dashed arrow) . In comparison, at steady-state, it appears that all of P23H that associates with Rho-S is multimeric (mainly dimers and trimers) (Fig. 2B) , whereas Rho-S that associates with P23H appears monomeric and core-glycosylated (Fig. 1C) .
Our observation of FRET between Rho-CFP and P23H-YFP established that the mutant and the wild-type protein are in close (Ͻ70 Å) proximity in cells that co-express the two proteins, consistent with the formation of hetero-oligomers between the mutant and wild-type proteins. In a previous study we reported that FRET between wild-type Rho-CFP and Rho-YFP could only be observed at very high expression levels (13) , an observation that we interpreted as indicative of aggregation of the wild-type protein when its expression exceeds the limited capacity of the secretory apparatus of HEK-293 cells to fold and process the protein. Our inability to detect FRET between Rho-CFP and Rho-YFP at low expression levels could result from an unfavorable orientation of the CFP and YFP fluorophores in the native dimer or from the limited sensitivity of this technique in highly scattering specimens. However, the absence of untagged WT rhodopsin in the Rho-S pulldown experiment (Fig. 2B) suggests that WT rhodopsin dimers in HEK-293 cells are labile to the detergent conditions used to solubilize the cells. By contrast, our ability to detect FRET between P23H-CFP and Rho-YFP at moderate expression levels and the formation of detergent-insoluble, higher order (i.e. Ͼ2) oligomers between P23H and Rho-S, implied that the interaction between the mutant and wild-type proteins, although possibly driven by intrinsic dimerization affinity, leads ultimately to the formation of highly stable, non-native oligomers.
The data reported here have important implications for understanding the mechanism of rhodopsin-linked ADRP. Mice lacking rhodopsin fail to form rod outer segments and develop progressive retinal degeneration, indicating that rhodopsin plays an important structural role in assembling or stabilizing the disk membrane (36, 37) . By contrast, mice heterozygous for the null allele develop outer segments and do not exhibit evidence of retinal degeneration (36) , suggesting the existence of a rhodopsin "threshold" somewhere between zero and one copy required for photoreceptor integrity. The dominant effect of mutant rhodopsin on the biosynthesis and/or maturation of the wild-type protein observed in our study would be predicted to diminish the amount of newly synthesized WT rhodopsin that matures beyond the ER in photoreceptors in the developing retina, thereby reducing the amount of protein that gets to the outer segment. Although it was not possible from our data to quantify the extent to which this dominant-negative effect would reduce WT rhodopsin in rod outer segments, our pulse-chase and steady-state measurements suggested that it is likely to be severe, i.e. below the apparent threshold for structural integrity.
Recently, we reported that misfolded mutant rhodopsin is also highly prone to form cytoplasmic aggregates that become sequestered in aggresomes when expressed in HEK cells and can interfere with the function of the ubiquitin proteasome system (13) . Pathogenesis of these diseases is widely held to be best explained by a gain-of-function mechanism in which mutations lead to the production of cytotoxic protein conformers that are highly prone to aggregate (14) . Although convincing histopathologic evidence linking a toxic gain-of-function mechanism to ADRP is still lacking, we are not aware of any evidence to rule out such a mechanism nor is it incompatible with the loss-of-function mechanism that we have documented in the present report. Understanding the relative contributions of these two mechanisms to ADRP will be important in the development of rational pharmacological interventions in these progressive blinding disorders.
